The Manufacturers Life Insurance Company Has $779,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

The Manufacturers Life Insurance Company trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 65.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 103,531 shares of the biotechnology company's stock after selling 195,621 shares during the quarter. The Manufacturers Life Insurance Company's holdings in BioCryst Pharmaceuticals were worth $779,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Franklin Resources Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 177.8% in the third quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company's stock valued at $1,968,000 after purchasing an additional 168,790 shares during the period. KBC Group NV increased its stake in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 4,537 shares during the last quarter. R Squared Ltd acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $48,000. China Universal Asset Management Co. Ltd. grew its stake in BioCryst Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 43,920 shares of the biotechnology company's stock worth $330,000 after buying an additional 4,129 shares during the period. Finally, Choreo LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $106,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX traded up $0.02 during trading on Monday, reaching $10.26. 1,998,484 shares of the company's stock were exchanged, compared to its average volume of 3,005,220. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $5.92 and a fifty-two week high of $11.11. The business has a 50 day moving average price of $8.11 and a 200-day moving average price of $7.96. The stock has a market capitalization of $2.15 billion, a P/E ratio of -16.80 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same period in the prior year, the business posted $0.28 EPS. The company's revenue for the quarter was up 40.8% compared to the same quarter last year. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

BCRX has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. JPMorgan Chase & Co. boosted their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. StockNews.com lowered BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, May 14th. Needham & Company LLC increased their price target on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Finally, JMP Securities restated a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $16.56.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.